Verition Fund Management
CRVS icon

Verition Fund Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Verition Fund Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,382
Closed -$165K – 2543
2025
Q4 		$165K Buy
+21,382
New +$169K ﹤0.01% 3232
2025
Q2 		– Sell
-24,413
Closed -$77.6K – 3670
2025
Q1 		$77.6K Buy
+24,413
New +$115K ﹤0.01% 3176
2021
Q3 		– Sell
-41,788
Closed -$112K – 1974
2021
Q2 		$112K Buy
+41,788
New +$115K ﹤0.01% 1705
2020
Q4 		– Sell
-146,730
Closed -$588K – 1153
2020
Q3 		$588K Buy
+146,730
New +$586K 0.01% 517

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return